Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.51 |
| ▸ | RELA | Q04206 | 4/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016759 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKNR1H2 | |
| SCHEMBL31454797 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKNR1H2 | |
| SCHEMBL31454839 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKNR1H2 | |
| SCHEMBL3906310 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKNR1H2 | |
| SCHEMBL13628664 | 0.88 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL6058662 | 0.86 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL5545237 | 0.86 | NFKB1 (0.50) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL14511588 | 0.86 | NFKB1 (0.50) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL6058659 | 0.86 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL6058660 | 0.86 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0628044-B1 | THERAPEUTIC NUCLEOSIDES | WELLCOME FOUND (GB) | 2003-07-23 | — | — | EP | claimed |
| CN-116162084-A | Pyran derivatives as CYP11A1 inhibitors | 奥赖恩公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-110139861-B | Pyran derivatives as CYP11A1 (cytochrome P450 monooxygenase 11A 1) inhibitors | 奥赖恩公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2020116662-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | 第一三共株式会社 | 2020-06-11 | — | — | WO | disclosed |
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
| US-7405065-B2 | Such as 1S,4R)-1-amino-4-(hydroxymethyl)-2-cyclopentene via N-acetylamino-alcohol hydrolase isolated from Rhodococcus, Gordona, Arthrobacter, Alcaligenes, Agrobacterium/Rhizobium, Bacillus, Pseudomonas or Alcaligenes/Bordetella | LONZA AG (CH) | 2008-07-29 | — | — | US | disclosed |
| CN-100374411-C | Process for preparing racemic or optically active 4- (hydroxymethyl) -2-cyclopentene derivatives | LONZA CO LTD (CH) | 2008-03-12 | — | — | CN | disclosed |
| CN-1302116-C | Process for preparing enantiomers of (1R, 4S) -or (1S, 4R) -1-amino-4- (hydroxymethyl) -2-cyclopentene derivatives | LONZE AG (CH) | 2007-02-28 | — | — | CN | disclosed |
| US-7115590-B1 | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R, cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| US-6252112-B1 | MIBCROBIAL HYDROLYSIS OF THE TITLE COMPOUND DERIVATIVE USING ENZYME HAVING N-ACETYLAMINO-ALCOHOL HYDROLASE OR PENICILLIN G ACYLASE ACTIVITY WITH SUBSEQUENT ACYLATION | LONZA A.G., (CH) | 2001-06-26 | — | — | US | disclosed |
| WO-2001042255-A1 | (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL | GLAXO GROUP LIMITED (GB) | 2001-06-14 | — | — | WO | disclosed |
| US-6156893-A | Process for the preparation of (1S,4R)- or (1R,4S)- 4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol | LONZA A.G. (CH) | 2000-12-05 | — | — | US | disclosed |
| WO-2000066557-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
| US-6137007-A | CHEMICAL INTERMEDIATES FOR NUCLEOSIDE, 4-2-(AMINO-6-CHLORO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL, WHICH IS AN INTERMEDIATE FOR 6-(CYCLOPROPYLAMINO)-DERIVATIVE | LONZA AG (CH) | 2000-10-24 | — | — | US | disclosed |
| CN-1220695-A | Process for the preparation of aminoalcohols and derivatives thereof | LONZA AG (CH) | 1999-06-23 | — | — | CN | disclosed |
| EP-0904348-A1 | PROCESS FOR THE PREPARATION OF AMINO ALCOHOLS AND DERIVATIVES THEREOF | LONZA AG (CH) | 1999-03-31 | — | — | EP | disclosed |
| CN-1201794-A | Process for the preparation of (1S,4R) -or (1R,4S) -4- (2-amino-6-chloro-9H-purin-9-yl) -2-cyclopentene-1-methanol or salts thereof | LONZA AG (CH) | 1998-12-16 | — | — | CN | disclosed |
| EP-0878548-A2 | Multistep process for the preparation of (1S,4R)- and/or (1R,4S)-4-(2-Amino-6-Chlor-9-H-purin-9-yl)-2-cyclopentene-1-methanol | LONZA AG (CH) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997045529-A1 | PROCESS FOR THE PREPARATION OF AMINO ALCOHOLS AND DERIVATIVES THEREOF | LONZA AG (CH) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | NFKB1 1110/4885NFKB2 1232/4885RELA 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.